Experimental pharmacokinetics of a new antiparkinsonian drug ADK-1113
https://doi.org/10.37489/2587-7836-2024-1-27-31
EDN: KNFZMY
Abstract
The pharmacokinetics of a new antiparkinsonian drug ADK-1113 after single intravenous and intragastric administrations in mice at doses of 10 and 20 mg/kg was studied. The absolute bioavailability was 10.1–16.3 % that indicates on potential possibility of preparing a dosage form for oral administration.
About the Authors
O. Yu. Kravtsova
FSBSI «Federal research center for innovator and emerging biomedical and pharmaceutical technologies»
Russian Federation
Russian Federation
Oxana Yu. Kravtsova – PhD, Cand. Sci. (Biology), leading research scientist of the laboratory of pharmacokinetics
Moscow
D. A. Dvoryaninov
FSBSI «Federal research center for innovator and emerging biomedical and pharmaceutical technologies»
Russian Federation
Russian Federation
Dmitriy A. Dvoryaninov – Junior researcher of the laboratory of pharmacokinetics
Moscow
G. B. Kolyvanov
FSBSI «Federal research center for innovator and emerging biomedical and pharmaceutical technologies»
Russian Federation
Russian Federation
Gennady B. Kolyvanov – PhD, Dr. Sci. (Biology), leading researcher of the laboratory of pharmacokinetics
Moscow
A. A. Litvin
FSBSI «Federal research center for innovator and emerging biomedical and pharmaceutical technologies»
Russian Federation
Russian Federation
Alexander A. Litvin – PhD, Dr. Sci. (Biology), Leading researcher of the laboratory of pharmacokinetics
Moscow
O. G. Gribakina
FSBSI «Federal research center for innovator and emerging biomedical and pharmaceutical technologies»
Russian Federation
Russian Federation
Oxana G. Gribakina – PhD, Cand. Sci. (Biology), senior research scientist of the laboratory of pharmacokinetics
Moscow
V. P. Zherdev
FSBSI «Federal research center for innovator and emerging biomedical and pharmaceutical technologies»
Russian Federation
Russian Federation
Vladimir P. Zherdev – PhD, Dr. Sci. (Med.), professor, Head of laboratory pharmacokinetics
Moscow
References
1. Kapitsa IG, Voronina TA. Antiparkinsonicheskaya aktivnost adamantylnogo proizvodnogo benzimidazola ADK-1113. Exper. Clin. Pharmacol. 2023;86(11S):68-68. (In Russ.). doi: 10/30906/ekf-2023-86s-68a.
2. Ragshaniya A, Kumar V, Tittal RK, Lal K. Nascent pharmacological advancement in adamantane derivatives. Arch Pharm (Weinheim). 2024 Mar;357(3):e2300595. doi: 10.1002/ardp.202300595.
3. Guidelines for conducting preclinical studies of drugs. Part one. Metodicheskie rekomendacii po provedeniyu doklinicheskih issledovanij farmakokinetiki novyh lekarstvennyh sredstv. Mironov AN. Moscow: Grif and K, 2012. P. 865-880. (In Russ.)
4. Kravtsova OYu, Dvoryaninov DA, Kolyvanov GB, et al. Quantification of a new antiparkinsonian agent ADK-1113 in mouse blood plasma by high performance liquid chromatography – tandem mass spectrometry. Exper. Clin. Pharmacol. 2024;87(2):6-12. (In Russ.). doi: 10/30906/0869-2092-2024-87-2-6-12.
5. Osnovy farmacokinetiki. Miroshnichenko II. Geotar-Med. Moscow: 2002 (In Russ.). ISBN 5-9231-0211-0.
6. Prikladnaya farmakokinetika: osnovnye polozheniya i klinicheskoe primenenie. Sergienko VI, Gelliff R, Bondareva IB. Moscow: Izd-vo Ros. akad. med. nauk. 2003. (In Russ.). ISBN 5790100317.
7. Farmacokinetika. Karkishenko NN, Khoronko VV, Sergeeva SA, Karkishenko VN. Rostov-na-Donu: 2001. (In Russ.). ISBN: 5-222-01504-1.
8. Edward H. Kerns and Li Di. Drug-like properties: concepts. structure design and methods: from ADME to toxicity optimization, 1st ed., Elsevir, Amsterdam-Boston-London, 2008.
9. Litvin EA. Biotrasformaciya i farmacokinetica novogo protivoparkinsonicheskogo preparata gimantana (experimentalnoe issledovanie). Autoabstract diss. candidate of biological sciences. Moscow; 2012. (In Russ.) https://clck.ru/3A9NQT.
Review
For citations:
Kravtsova O.Yu., Dvoryaninov D.A., Kolyvanov G.B., Litvin A.A., Gribakina O.G., Zherdev V.P. Experimental pharmacokinetics of a new antiparkinsonian drug ADK-1113. Pharmacokinetics and Pharmacodynamics. 2024;(1):27-31. (In Russ.) https://doi.org/10.37489/2587-7836-2024-1-27-31. EDN: KNFZMY
Views:
293
Email this article 